Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Phase 2

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Clarithromycin
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2007-03-09

Last Posted Date: 2019-11-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00445692

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: pneumococcal polyvalent vaccine
Drug: lenalidomide

First Posted Date: 2007-03-09

Last Posted Date: 2015-08-24

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 22

Registration Number: NCT00445484

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2007-02-23

Last Posted Date: 2014-01-13

Lead Sponsor: Georg Aue, M.D.

Target Recruit Count: 33

Registration Number: NCT00439231

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Maintenance Therapy Using Lenalidomide in Myeloma

Phase 3

Completed

Conditions: Myeloma

Interventions: Drug: placebo
Drug: lenalidomide

First Posted Date: 2007-02-01

Last Posted Date: 2019-04-26

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 614

Registration Number: NCT00430365

Locations: 🇫🇷
CHRU Hôpital Bretonneau, Tours, France
🇫🇷
Centre hospitalier, Troyes, France
🇧🇪
ZNA Middelheim, Antwerpen, Belgium

and more 69 locations

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Phase 2

Conditions: Myelodysplastic Syndromes

First Posted Date: 2007-01-18

Last Posted Date: 2007-03-12

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 49

Registration Number: NCT00424229

Locations: 🇫🇷
Hopital Archet, Nice, France
🇫🇷
CHRU Hurriez, Lille, France
🇫🇷
CHU Angers, Angers, France

and more 8 locations

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2007-01-11

Last Posted Date: 2012-05-21

Lead Sponsor: Celgene Corporation

Target Recruit Count: 587

Registration Number: NCT00420849

Locations: 🇦🇹
Wilhelminenspital, Vienna, Montlearstrasse 37, Austria
🇮🇪
St James's Hospital, Dublin, Ireland
🇪🇸
H. Clínico de Salamanca, Salamanca, Spain

and more 2 locations

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia, B-Cell, Chronic

Interventions: Drug: lenalidomide

First Posted Date: 2007-01-08

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 52

Registration Number: NCT00419250

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Indiana University Medical center, Indianapolis, Indiana, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 32 locations

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-12-22

Last Posted Date: 2012-07-06

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 32

Registration Number: NCT00415064

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-12-22

Last Posted Date: 2011-07-08

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 14

Registration Number: NCT00415116

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin's

Interventions: Drug: lenalidomide

First Posted Date: 2006-12-19

Last Posted Date: 2017-03-01

Lead Sponsor: Celgene

Target Recruit Count: 217

Registration Number: NCT00413036

Locations: 🇺🇸
Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States
🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸
Access Clinical Research, Rancho Mirage, California, United States

and more 45 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy